Admin_Adham
The FDA has approved Medtronic’s MiniMed 780G automated insulin delivery (AID) system for use in type 2 diabetes (T2D).
At the same time, FDA also cleared the MiniMed SmartGuard algorithm as an “interoperable automated glycemic controller,” which enables integration with a new sensor called Instinct for type 1 diabetes (T1D). The Instinct, made by Abbott specifically for use with MiniMed AID and smart pen products, is smaller than currently marketed sensors and lasts up to 15 days.
The MiniMed 780G system is available for people with T1D aged 7 years or older and for adults aged 18 years or older with insulin-requiring T2D, with the Guardian 4 sensor and the Simplera Sync sensor.
Preorders for Simplera Sync sensor will begin later this month.
Medtronic and Abbott are working to finalize the regulatory process so that the Instinct sensor can be ordered with the MiniMed 780 for T1D first. After that, Medtronic will submit an application for the use of the MiniMed 780G integration with the Instinct for T2D.
Other AIDs, including the Omnipod 5 and the Control-IQ+ algorithm used with Tandem’s t:slim X2 and Mobi insulin pumps, have also been cleared for use in T2D.
Miriam E. Tucker is a freelance journalist based in the Washington, DC, area. She is a regular contributor to Medscape, with other work appearing in the Washington Post, NPR’s Shots blog, and Diatribe. She is on X @MiriamETucker and BlueSky @miriametucker.bsky.social.
